AI Article Synopsis

  • Alzheimer's disease is a complex illness with ongoing research focused on new treatments, particularly those targeting amyloid-beta, which is essential to its development.
  • A study surveyed caregivers, neurologists, and payors in the U.S. to evaluate their preferences for treatment options using a multicriteria decision analysis, which broke down various decision factors and preferences.
  • Results showed that all stakeholder groups prioritized drug efficacy and the benefits to patients, while cost considerations were deemed less significant in the decision-making process.

Article Abstract

Introduction: Alzheimer's disease (AD) is a chronic neurodegenerative disorder associated with a high burden of illness. New therapies under development include agents that target amyloid-beta (Aβ), a key component in AD pathogenesis. Understanding the decision-making process for new AD drugs would help determine if such therapies should be adopted by society. Multicriteria decision analysis (MCDA) was applied to three key stakeholder groups to assess treatment alternatives for AD based on a multitude of decision trade-offs covering main components of care.

Methods: AD caregivers (n = 117), neurologists (n = 90), and payors (n = 90) from the USA received an online survey. The decision problem was broken down into four decision criterion and 12 subcriteria for two treatment scenarios: an Aβ-targeted therapy vs. the standard of care (SOC). Respondents were asked to indicate how much they preferred one option over another on a scale from 1 (equal preference) to 9 (high preference) based on each criterion and subcriterion. The decision criteria and subcriteria were weighted and presented as partial utility scores (pUS), with higher scores suggesting an increased preference for that decision-making component.

Results: Caregivers and payors applied the highest value to need for intervention (mean pUS = 0.303 and 0.259) and clinical outcomes (mean pUS = 0.286 and 0.377). In contrast, neurologists placed the highest value on clinical outcomes and types of benefits (mean pUS = 0.436 and 0.248). When decision subcriteria were examined, efficacy (mean pUS = 0.115, 0.219, and 0.166) and the type of patient benefits (mean pUS = 0.135, 0.178, and 0.126) were among the most valued by caregivers, neurologists, and payors.

Conclusion: All groups placed the highest value on drug efficacy and types of benefit derived by patients. In contrast, cost implications were among the least important aspects in their decision-making.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837350PMC
http://dx.doi.org/10.1007/s40120-022-00423-yDOI Listing

Publication Analysis

Top Keywords

alzheimer's disease
8
multicriteria decision
8
decision analysis
8
caregivers neurologists
8
clinical outcomes
8
decision
7
treatment preference
4
preference alzheimer's
4
disease multicriteria
4
caregivers
4

Similar Publications

Mild cognitive impairment (MCI) refers to cognitive alterations with preservation of functionality. Individuals with this diagnosis have a higher risk of developing dementia. Non-pharmacological interventions, such as physical exercise, are beneficial for the cognition of this population.

View Article and Find Full Text PDF

Dietary Methionine Restriction Alleviates Cognitive Impairment in Alzheimer's Disease Mice via Sex-Dependent Modulation on Gut Microbiota and Tryptophan Metabolism: A Multiomics Analysis.

J Agric Food Chem

January 2025

Laboratory of Functional Chemistry and Nutrition of Food, College of Food Science and Engineering, Northwest A&F University, Yangling, Shaanxi 712100, China.

Plant-based foods with low methionine contents have gained increasing interest for their potential health benefits, including neuroprotective effects. Methionine restriction (MR) linked to a plant-based diet has been shown to mitigate neurodegenerative diseases such as Alzheimer's disease (AD) through mechanisms that involve the gut microbiota. In this study, a 16-week MR diet (0.

View Article and Find Full Text PDF

The number of cases of Alzheimer's disease (AD) characterized by progressive amnestic syndrome is dramatically increased with population aging. It is urgent to detect and diagnose this disease early. The state of amyloid-beta protein 1-42 (Aβ) was commonly regarded as a hallmark for early diagnosis of AD.

View Article and Find Full Text PDF

G9a/GLP Modulators: Inhibitors to Degraders.

J Med Chem

January 2025

SANKEN, Osaka University, Mihogaoka, Ibaraki-shi, Osaka 567-0047, Japan.

Histone methylation, a crucial aspect of epigenetics, intricately involves specialized enzymes such as G9a, a histone methyltransferase (HMT) catalyzing the methylation of histone H3 lysine 9 (H3K9) and H3K27. Apart from histone modification, G9a regulates essential cellular processes such as deoxyribonucleic acid (DNA) replication, damage repair, and gene expression via modulating DNA methylation patterns. The dysregulation and overexpression of G9a are intricately linked to cancer initiation, progression, and metastasis, making it a compelling target for anticancer therapy.

View Article and Find Full Text PDF

Cognitive impairment, changes in mood, and decrease in fine motor skills are some of the most common symptoms experienced by individuals with Alzheimer's Disease (AD). This study aimed to investigate the effects of the Turkish intelligence and strategy game Mangala on cognitive functions, anxiety, depression, and fine motor skills in individuals with AD. In this randomized controlled study, 37 participants were divided into Mangala Group (MG) and Control Group (CG).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!